Efficacy and safety of dupilumab in a patient with metastatic clear cell renal cell carcinoma
This case report evaluated the efficacy and safety of dupilumab, a monoclonal antibody targeting interleukin-4 and interleukin-13, in a patient with atopic dermatitis (AD) and a history of metastatic renal cancer. Over 20 months of follow-up, the patient experienced significant improvement in AD sym...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-11-01
|
| Series: | Journal of International Medical Research |
| Online Access: | https://doi.org/10.1177/03000605241297551 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841543427580231680 |
|---|---|
| author | César Ferreira Egídio Freitas Tiago Torres |
| author_facet | César Ferreira Egídio Freitas Tiago Torres |
| author_sort | César Ferreira |
| collection | DOAJ |
| description | This case report evaluated the efficacy and safety of dupilumab, a monoclonal antibody targeting interleukin-4 and interleukin-13, in a patient with atopic dermatitis (AD) and a history of metastatic renal cancer. Over 20 months of follow-up, the patient experienced significant improvement in AD symptoms without any recurrence of cancer. In addition to not stimulating carcinogenesis, dupilumab might synergistically inhibit tumor-induced immunosuppression, thereby potentially preventing tumor progression. This case suggests that dupilumab could be a viable treatment option for patients with AD and a history of solid neoplasms, filling a critical gap in current therapeutic approaches. Current evidence indicates that dupilumab does not promote cancer progression, but further research is necessary to confirm its long-term safety in this population. To establish robust scientific evidence and develop precise clinical guidelines, future studies should be randomized, controlled, and large-scale. This will help provide a definitive understanding of the safety and efficacy of dupilumab in patients with a history of cancer and inform clinical practice. In summary, although the initial findings are promising, comprehensive research is essential to ensure the optimal management of AD in patients with a history of malignancies. |
| format | Article |
| id | doaj-art-d9801dc5d2314f069c4462789aad11a1 |
| institution | Kabale University |
| issn | 1473-2300 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of International Medical Research |
| spelling | doaj-art-d9801dc5d2314f069c4462789aad11a12025-01-13T12:03:35ZengSAGE PublishingJournal of International Medical Research1473-23002024-11-015210.1177/03000605241297551Efficacy and safety of dupilumab in a patient with metastatic clear cell renal cell carcinomaCésar FerreiraEgídio FreitasTiago TorresThis case report evaluated the efficacy and safety of dupilumab, a monoclonal antibody targeting interleukin-4 and interleukin-13, in a patient with atopic dermatitis (AD) and a history of metastatic renal cancer. Over 20 months of follow-up, the patient experienced significant improvement in AD symptoms without any recurrence of cancer. In addition to not stimulating carcinogenesis, dupilumab might synergistically inhibit tumor-induced immunosuppression, thereby potentially preventing tumor progression. This case suggests that dupilumab could be a viable treatment option for patients with AD and a history of solid neoplasms, filling a critical gap in current therapeutic approaches. Current evidence indicates that dupilumab does not promote cancer progression, but further research is necessary to confirm its long-term safety in this population. To establish robust scientific evidence and develop precise clinical guidelines, future studies should be randomized, controlled, and large-scale. This will help provide a definitive understanding of the safety and efficacy of dupilumab in patients with a history of cancer and inform clinical practice. In summary, although the initial findings are promising, comprehensive research is essential to ensure the optimal management of AD in patients with a history of malignancies.https://doi.org/10.1177/03000605241297551 |
| spellingShingle | César Ferreira Egídio Freitas Tiago Torres Efficacy and safety of dupilumab in a patient with metastatic clear cell renal cell carcinoma Journal of International Medical Research |
| title | Efficacy and safety of dupilumab in a patient with metastatic clear cell renal cell carcinoma |
| title_full | Efficacy and safety of dupilumab in a patient with metastatic clear cell renal cell carcinoma |
| title_fullStr | Efficacy and safety of dupilumab in a patient with metastatic clear cell renal cell carcinoma |
| title_full_unstemmed | Efficacy and safety of dupilumab in a patient with metastatic clear cell renal cell carcinoma |
| title_short | Efficacy and safety of dupilumab in a patient with metastatic clear cell renal cell carcinoma |
| title_sort | efficacy and safety of dupilumab in a patient with metastatic clear cell renal cell carcinoma |
| url | https://doi.org/10.1177/03000605241297551 |
| work_keys_str_mv | AT cesarferreira efficacyandsafetyofdupilumabinapatientwithmetastaticclearcellrenalcellcarcinoma AT egidiofreitas efficacyandsafetyofdupilumabinapatientwithmetastaticclearcellrenalcellcarcinoma AT tiagotorres efficacyandsafetyofdupilumabinapatientwithmetastaticclearcellrenalcellcarcinoma |